Veritas In Silico Inc is a Japan-based company primarily engaged in the pharmaceutical discovery platform business. The main business is small molecule drug discovery targeting messenger ribonucleic acid (mRNA) using the ibVIS platform, which integrates digital technology including in silico ribonucleic acid (RNA) structural analysis technology and drug discovery technology, through joint drug discovery research with pharmaceutical companies to create mRNA-targeted small molecule drugs.

Employees

Sector

Biotechnology & Medical Research

Calendar

11-10 Earnings release - Q3 2026

More about the company

Quotes

Date	Price	Change	Volume
26-08-20	JP¥445.00	+7.23%	60,100
26-08-19	JP¥415.00	-1.19%	20,300
26-08-18	JP¥420.00	-0.47%	11,400
26-08-17	JP¥422.00	0.00%	9,200
26-08-14	JP¥422.00	-1.86%	11,800

Delayed Quote Japan Exchange

More quotes

Delayed Japan Exchange 02:30:00 2026-08-20 EDT			5-day change	1st Jan Change
445.00 ^JPY	+7.23%		+9.61%	-7.29%

08-05	Veritas In Silico Inc. Reports Earnings Results for the Half Year Ended June 30, 2026	CI
08-03	Veritas In Silico, Mitsubishi Gas Chemical File Joint Patent for Cancer Drug	MT

Market Cap	2.89B 18.16M 15.55M 14.53M 13.32M 25.02M 1.74B 25.53M 171M 66.97M 873M 68.19M 66.7M	P/E 2024	-23.8x	P/E 2025	-7.32x
Enterprise Value	1.06B 6.68M 5.72M 5.34M 4.9M 9.2M 639M 9.39M 62.79M 24.63M 321M 25.08M 24.53M	EV / Sales 2024	18.2x	EV / Sales 2025	14.1x
Free-Float	49.81%	Yield 2024 *	-	Yield 2025	-

08-05	Veritas In Silico Inc. Reports Earnings Results for the Half Year Ended June 30, 2026	CI
08-03	Veritas In Silico, Mitsubishi Gas Chemical File Joint Patent for Cancer Drug	MT
05-11	SpiroChem AG and Veritas in Silico Inc. Enter Joint Research Agreement to Initiate Discovery of Next Generation mRNA Binding Chemical Matter	CI
04-13	Veritas In Silico and Takeda Mutually Terminate mRNA-Targeted Drug Research Collaboration	MT
04-13	Veritas in Silico Inc. Terminates Collaborative Drug Discovery Research with Takeda Pharmaceutical Company Limited	CI
02-11	Veritas in Silico Inc. Provides Earnings Guidance for the Fiscal Year Ending December 31, 2026	CI
02-11	Veritas In Silico Inc. Reports Earnings Results for the Full Year Ended December 31, 2025	CI
01-26	SpiroChem AG and Veritas In Silico Inc. Sign MoU to Accelerate Discovery of Next Generation RNA Binding Chemical Matter	CI
01-19	The Jikei University School of Medicine and Veritas In Silico Inc. Announce Patent Publication for Novel Nucleic Acid Therapeutic Targeting Amyotrophic Lateral Sclerosis	CI
01-19	Japan Shares Start Week in Red as Trump Threatens More Tariffs on Europe	MT
01-19	Veritas In Silico, Jikei University Patent ALS Nucleic Acid Therapy	MT
12-22	Veritas In Silico Files Patent for mRNA-Targeted Kidney Injury Drug	MT
12-15	Veritas in Silico, Inc. Announces Completion of Patent Examination and Patent Grant Procedures for Drug Delivery System "Perfusio"	CI

1 day	+7.23%
1 week	+9.61%
Current month	+9.61%
1 month	+6.46%
3 months	+10.97%
6 months	-8.44%
Current year	-7.29%

Veritas In Silico Inc. Stock

Stocks

130A

JP3155340007

Biotechnology & Medical Research

Valuation: Veritas In Silico Inc.

Chart: Veritas In Silico Inc.

Latest news : Veritas In Silico Inc.

Quotes and Performance

Course Extremes

Managers and Directors: Veritas In Silico Inc.

Other Biotechnology & Medical Research

Financials

Company Profile

Quotes

Manager	Title	Age	Since
Shingo Nakamura CEO	Chief Executive Officer	54	2016-11-16
Hiroaki Hagiwara DFI	Director of Finance/CFO	57	2021-12-31
Isao Koda PRN	Corporate Officer/Principal	69	2018-11-30

Director	Title	Age	Since
Shingo Nakamura BRD	Director/Board Member	54	2016-11-16
Kinichiro Kominami BRD	Director/Board Member	59	2019-07-31
Hiroaki Hagiwara BRD	Director/Board Member	57	2024-02-29

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
VERITAS IN SILICO INC.	+7.23%	+9.61%	-39.78%	-	16.99M
LONZA GROUP AG	+1.14%	+3.46%	+4.57%	+24.14%	50.5B
REVOLUTION MEDICINES, INC.	-1.36%	+3.15%	+479.46%	+614.84%	46.01B
BEONE MEDICINES AG	-2.04%	+2.82%	+18.13%	+91.23%	42.85B
IQVIA HOLDINGS INC.	+2.72%	+5.93%	+33.12%	+19.66%	41.03B
CELLTRION, INC.	0.00%	-3.91%	+17.87%	+47.98%	32.02B
MEDPACE HOLDINGS, INC.	+0.72%	+2.62%	+32.57%	+145.37%	16.98B
ASCENDIS PHARMA A/S	-1.85%	-0.25%	-	-	17.05B
EUROFINS SCIENTIFIC SE	+3.06%	+4.63%	+7.40%	+35.00%	14.3B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	+0.50%	+2.49%	+83.90%	+46.53%	13.84B
Average	+1.01%	+2.03%	+70.80%	+128.09%	27.46B
Weighted average by Cap.	+0.18%	+2.37%	+104.13%	+152.88%

	2024	2025
Net sales	195M 1.22M 1.05M 980K 898K 1.69M 117M 1.72M 11.51M 4.52M 58.88M 4.6M 4.5M	91.14M 573K 491K 459K 421K 790K 54.83M 806K 5.39M 2.11M 27.57M 2.15M 2.11M
Net income	-236M -1.49M -1.27M -1.19M -1.09M -2.05M -142M -2.09M -13.99M -5.49M -71.53M -5.59M -5.46M	-426M -2.68M -2.29M -2.14M -1.96M -3.69M -256M -3.76M -25.18M -9.88M -129M -10.06M -9.84M
Net Debt	-2.17B -13.67M -11.7M -10.94M -10.03M -18.84M -1.31B -19.22M -129M -50.42M -657M -51.34M -50.22M	-1.83B -11.48M -9.83M -9.19M -8.42M -15.82M -1.1B -16.14M -108M -42.34M -552M -43.12M -42.18M

1 week	410	451
1 month	396	477
Current year	390	586
1 year	390	793
3 years	390	3,475
5 years	390	3,475
10 years	390	3,475